融资活动总结 - Auddia公司成功完成了一次公开募股 以每股2.36美元的价格发行了总计5,084,743股普通股（或其等价物）以及可购买最多5,084,743股普通股的认股权证 认股权证的行权价格同样为每股2.36美元 [1] - 此次发行募集的毛收入约为1200万美元 在扣除配售代理费和其他发行费用之前 公司计划将净收益用于营运资金和一般公司用途 [2] - Dawson James证券公司担任此次发行的独家配售代理 [2] 证券发行细节 - 本次发行的证券依据一份S-1表格的注册声明（文件号333-294887） 该声明已于2026年4月23日获得美国证券交易委员会（SEC）的生效批准 [3] - 认股权证在发行后可立即行权 其到期日为以下两者中较早者：(i) 根据2026年2月17日签署的特定合并协议及计划（可能经修订）完成相关交易 或 (ii) 发行日期的五周年纪念日 [1] 公司业务与产品介绍 - Auddia是一家技术公司 其构建了专有的人工智能平台 用于音频识别和分类 旨在重塑消费者与音频互动的方式 [1] - 公司的业务不仅致力于改变消费者与AM/FM广播、播客等音频内容的互动方式 也致力于改变艺术家和唱片公司推广音乐、接触主流广播听众的方式 [5] - 公司的Discovr Radio是首个能为艺术家提供保证性广播听众曝光的音乐推广平台 [5] - 公司的旗舰音频超级应用faidr提供了多项行业首创功能 包括：在任何AM/FM音乐电台的无广告收听、跨任何AM/FM音乐电台的内容跳过、一键跳过整个播客广告时段以及集成的艺术家发现体验 [5][7]

WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results from its Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4R bispecific antibody ATI-052 and the results of its lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138 before the opening of the financial marke ...

Strong net interest margin and operating efficiency support tangible book value expansionHAMILTON, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- First Bank (Nasdaq Global Market: FRBA) ("the Bank") today announced results for the first quarter of 2026. Net income for the first quarter of 2026 was $7.6 million, or $0.30 per diluted share, compared to $9.4 million, or $0.37 per diluted share, for the first quarter of 2025. Return on average assets, return on average equity and return on average tangible equityi fo ...

- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier - WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it will present new preclinical data demonstrating the ability of the FORCE platform to cross the blood-brain barrier (BBB) and enable robu ...

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, and one oral ...

LIMASSOL, Cyprus, April 27, 2026 (GLOBE NEWSWIRE) -- Robin Energy Ltd. (NASDAQ: RBNE) (“Robin Energy” or the “Company”), an international ship-owning company providing energy transportation services globally, announces today the final results of its tender offer (the “Offer”), which expired at 5:00 P.M. Eastern time on April 23, 2026. Based on the final count by Broadridge Corporate Issuer Solutions LLC, the depositary for the tender offer, 1,909,473 common shares (the “Shares”) were properly tendered and n ...

ASGCT会议摘要接受与展示详情 - TScan Therapeutics宣布其摘要已被接受 将于2026年5月11日至15日在美国基因与细胞治疗学会第29届年会上进行海报展示[1] - 展示标题为“旨在消除异基因造血细胞移植后残留疾病并预防复发的新型CD45靶向TCR-T细胞疗法” 展示时间为5月12日美国东部时间下午5:00-6:30[2][3] - 展示结束后 相关材料将公布在公司官网的“出版物”栏目中[3] 公司核心业务与研发管线 - TScan Therapeutics是一家临床阶段的生物技术公司 专注于开发用于治疗癌症患者的T细胞受体工程化T细胞疗法[1][4] - 公司的主要TCR-T候选疗法正在开发中 用于治疗血液系统恶性肿瘤患者 旨在预防异基因造血细胞移植后的复发[4] - 公司正处于开发用于治疗实体瘤的体内工程方法的早期阶段[4] - 公司同时应用其靶点发现平台 在多种T细胞介导的自身免疫性疾病中探索新靶点[4]

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today presents new research on a TALE-based epigenetic editing approach, that does not cut or permanently modify the DNA sequence, making it a potentially safer alternative for genome editing, at the American Society of Gene and Cell Therapy (ASGCT) annual meeting, that ...

公司核心动态 - 公司Charlton Aria Acquisition Corporation (NASDAQ: CHARU)于2026年4月24日获得其发起人ST Sponsor II Limited向信托账户存入的850,000美元资金 从而将完成初始业务合并的截止日期延长至2026年7月25日 [1] - 根据公司第二次修订及重述的组织章程大纲及细则 公司原需在2026年4月25日或首次公开募股完成后的18个月内完成初始业务合并 但发起人可通过每次存入850,000美元的方式 将期限每次延长三个月 最多可延长两次 总计最高可存入1,700,000美元 [2] 公司背景与业务范围 - Charlton Aria Acquisition Corporation是一家根据开曼群岛法律注册成立的豁免有限责任公司 是一家特殊目的收购公司(空白支票公司) 旨在与一个或多个企业或实体进行合并、股份交换、资产收购、股份购买、资本重组、重组或类似的业务组合 [3] - 公司寻找潜在目标业务的努力不限于特定行业或地理区域 [3]

MCLEAN, Va., April 27, 2026 (GLOBE NEWSWIRE) -- Freddie Mac (OTCQB: FMCC) today posted to its website its Monthly Volume Summary for March 2026, which provides information on Freddie Mac’s mortgage-related portfolios, securities issuance, risk management, delinquencies, debt activities, and other investments. Freddie Mac’s mission is to make home possible for families across the nation. We promote liquidity, stability and affordability in the housing market throughout all economic cycles. Since 1970, we hav ...